echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Jiahe Biologics STING agonist GB492 clinical trial application accepted

    Jiahe Biologics STING agonist GB492 clinical trial application accepted

    • Last Update: 2021-04-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, through the official website of Jiahe Biotechnology, it was learned that its GB492 (IMSA101) Stimulator of interferon genes (STING) agonist has been officially accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration.


    The purpose of the clinical study for GB492 (IMSA101) application acceptance is to determine the phase II recommended dosing for GB492 monotherapy and combined recombinant anti-PD-1/L1 humanized monoclonal antibody (anti-PD-1/L1 monoclonal antibody) treatment Dose (RP2D), plan to enroll subjects with advanced malignancies who are refractory or unsuitable for standard treatment, including but not limited to melanoma, triple-negative breast cancer, liver cancer, head and neck cancer, renal cell carcinoma, gastroesophageal cancer And other cancer species.


    It is understood that a number of previous studies have shown that interferon gene stimulating factor (STING) agonists can be used in combination with immune checkpoint inhibitors (ICI) as a new immunostimulatory therapy that can enhance the efficacy of cancer immunotherapy.


    It is reported that Jiahe Biologics follow-up plans to jointly develop GB492 (IMSA101) and its anti-PD-1 antibody Gerolizumab (GB226) for the treatment of solid tumors.


    GB492 (IMSA101) is an agonist of Stimulator of interferon genes (STING), which was granted an exclusive license agreement from ImmuneSensor Therapeutic by Jiahe Biologics in June 2020.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.